{"disease":{"id":"response","name":"response"},"drugs":{"marketed":[{"drug_id":"upadacitinib","indication_name":"Moderately to severely active rheumatoid arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active ankylosing spondylitis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active non-radiographic axial spondyloarthritis with objective signs of inflammation in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active psoriatic arthritis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Active psoriatic arthritis in pediatric patients 2 years of age and older with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Moderately to severely active ulcerative colitis in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"upadacitinib","indication_name":"Moderately to severely active Crohn's disease in adults with inadequate response or intolerance to TNF blockers","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rinvoq","generic_name":"upadacitinib","company_name":"AbbVie Inc.","drug_phase":"marketed","molecular_target":"Janus kinase (JAK) enzymes, particularly JAK1 and JAK2","drug_class":"JAK inhibitor","quality_score":86,"revenue":"5300","mechanism":"JAK inhibitor that prevents STAT phosphorylation and activation in cytokine signaling pathways."},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-100-mg","indication_name":"Moderate to severe atopic dermatitis in children aged 12 years and older who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 100 mg","generic_name":"abrocitinib-100-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"Janus kinase inhibitor","quality_score":48,"revenue":"284","mechanism":""},{"drug_id":"abrocitinib-200-mg","indication_name":"Moderate to severe atopic dermatitis in adults who have had an inadequate response or intolerance to one or more biologics, or who are candidates for systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Abrocitinib 200 mg","generic_name":"abrocitinib-200-mg","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"JAK1","drug_class":"JAK inhibitor","quality_score":40,"revenue":"284","mechanism":""},{"drug_id":"89zr-zr-crefmirlimab-berdoxam","indication_name":"Plaquenil-resistant or -intolerant adult patients with cutaneous T-cell lymphoma (CTCL) who have had an inadequate response or are intolerant to at least one prior systemic therapy","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"[89Zr]Zr-crefmirlimab berdoxam","generic_name":"89zr-zr-crefmirlimab-berdoxam","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Fibroblast Activation Protein (FAP)","drug_class":"Radiolabeled Monoclonal Antibody","quality_score":26,"revenue":null,"mechanism":""},{"drug_id":"etrasimod","indication_name":"Maintenance of clinical response and endoscopic remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."},{"drug_id":"etrasimod","indication_name":"Maintenance of clinical response and endoscopic remission in adults with moderately to severely active Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Etrasimod","generic_name":"etrasimod","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":64,"revenue":null,"mechanism":"Etrasimod is an S1P receptor modulator that blocks lymphocyte egress from lymphoid organs, reducing peripheral blood lymphocytes."},{"drug_id":"aldactone","indication_name":"Edema in nephrotic syndrome with inadequate response to other treatments","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Aldactone","generic_name":"Spironolactone","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Aldosterone receptors at aldosterone-dependent sodium-potassium exchange site in distal convoluted renal tubule","drug_class":"Potassium-sparing diuretic, aldosterone antagonist","quality_score":66,"revenue":null,"mechanism":"Aldosterone antagonist causing increased sodium and water excretion while retaining potassium."},{"drug_id":"velsipity","indication_name":"Maintenance of clinical response and remission in adults with moderately to severely active ulcerative colitis","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"Etrasimod Arginine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":67,"revenue":null,"mechanism":"Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs."},{"drug_id":"velsipity","indication_name":"Maintenance of clinical response and remission in adults with moderately to severely active Crohn's disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Velsipity","generic_name":"Etrasimod Arginine","company_name":"Pfizer Inc.","drug_phase":"marketed","molecular_target":"Sphingosine 1-phosphate (S1P) receptors 1, 4, and 5","drug_class":"Sphingosine 1-phosphate receptor modulator","quality_score":67,"revenue":null,"mechanism":"Etrasimod binds S1P receptors 1, 4, and 5, blocking lymphocyte egress from lymphoid organs."},{"drug_id":"imetelstat","indication_name":"low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rytelo","generic_name":"IMETELSTAT","company_name":"Geron","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Rytelo works by inhibiting the activity of telomerase, an enzyme that helps cancer cells grow and divide."}],"pipeline":[],"offLabel":[],"totalMarketed":18,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06666647","title":"Response Times in Danish Emergency Medical Services","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2500000,"lead_sponsor_name":"Peter Martin Hansen","has_results":false},{"nct_id":"NCT06622304","title":"Exploring the Effects of Antihypertensive and Lipid-Lowering Drugs on Inflammatory Cytokine Levels","phase":"","overall_status":"COMPLETED","enrollment_count":250736,"lead_sponsor_name":"Guangzhou Institute of Respiratory Disease","has_results":false},{"nct_id":"NCT05520242","title":"Use of Animations Movies to Increase Response in a National Health Survey","phase":"NA","overall_status":"COMPLETED","enrollment_count":201200,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT04951973","title":"Deep Learning Based Early Warning Score in Rapid Response Team Activation","phase":"","overall_status":"UNKNOWN","enrollment_count":50000,"lead_sponsor_name":"Seoul National University Hospital","has_results":false},{"nct_id":"NCT03046368","title":"Personalization of Cover Letter and Response Rate","phase":"NA","overall_status":"COMPLETED","enrollment_count":25000,"lead_sponsor_name":"University of Southern Denmark","has_results":false},{"nct_id":"NCT03441503","title":"Child HCAHPS: Automated Day of Discharge Survey","phase":"NA","overall_status":"TERMINATED","enrollment_count":23578,"lead_sponsor_name":"Boston Children's Hospital","has_results":false},{"nct_id":"NCT07116447","title":"Impact of Alcohol Health Messages in a Real-world Online Retail Setting","phase":"NA","overall_status":"COMPLETED","enrollment_count":11719,"lead_sponsor_name":"World Health Organization","has_results":false},{"nct_id":"NCT04330261","title":"Clinical Characteristics and Outcomes of Pediatric COVID-19","phase":"","overall_status":"COMPLETED","enrollment_count":10610,"lead_sponsor_name":"University of Calgary","has_results":false},{"nct_id":"NCT04724785","title":"Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":10000,"lead_sponsor_name":"The Second Affiliated Hospital of Chongqing Medical University","has_results":false},{"nct_id":"NCT05151094","title":"Registry of Hospitalized Patients in University Hospital Dubrava Respiratory Center","phase":"","overall_status":"UNKNOWN","enrollment_count":6000,"lead_sponsor_name":"University Hospital Dubrava","has_results":false},{"nct_id":"NCT04799808","title":"Saxon SARS-CoV-2 Infection and Vaccination Study in Dialysis Patients, Solid Organ Recipients and Staff","phase":"","overall_status":"UNKNOWN","enrollment_count":3500,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT07319065","title":"Left Ventricular Myocardial Work for Predicting Response to CRT","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":3240,"lead_sponsor_name":"First Hospital of China Medical University","has_results":false},{"nct_id":"NCT03892577","title":"Real-world Study for Patients With Advanced Hepatobiliary Tumors","phase":"","overall_status":"UNKNOWN","enrollment_count":3000,"lead_sponsor_name":"Peking Union Medical College Hospital","has_results":false},{"nct_id":"NCT06531681","title":"Precision Radiotherapy for Tumours Using Magnetic Resonance-guided Linear Accelerator (MR-Linac)","phase":"","overall_status":"RECRUITING","enrollment_count":3000,"lead_sponsor_name":"The Second Affiliated Hospital of Hainan Medical University","has_results":false},{"nct_id":"NCT03910140","title":"TILA-TACE in Treatment of Hepatocellular Carcinoma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":2000,"lead_sponsor_name":"Second Affiliated Hospital, School of Medicine, Zhejiang University","has_results":false},{"nct_id":"NCT03002259","title":"Dexamethasone for Cardiac Surgery-II Trial","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":1956,"lead_sponsor_name":"Bayside Health","has_results":false},{"nct_id":"NCT05361603","title":"Acceptability of Simultaneous Screening for Viral Hepatitis B, C and HIV Among Drug Users in Non-conventional Structures","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"University Hospital, Limoges","has_results":false},{"nct_id":"NCT04507737","title":"Rapid Response Teams - How and Who?","phase":"NA","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"Nordsjaellands Hospital","has_results":false},{"nct_id":"NCT06915298","title":"Impact of Alcohol Labels in a Real-World Setting","phase":"NA","overall_status":"COMPLETED","enrollment_count":1410,"lead_sponsor_name":"World Health Organization","has_results":false},{"nct_id":"NCT03500172","title":"HIV Treatment Retention Interventions for Women Living With HIV (Siyaphambili Study)","phase":"NA","overall_status":"COMPLETED","enrollment_count":1391,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":true},{"nct_id":"NCT03229538","title":"STeroids to REduce Systemic Inflammation After Infant Heart Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1263,"lead_sponsor_name":"Kevin Hill","has_results":true},{"nct_id":"NCT03297866","title":"Effectiveness of Different Incentive Models in Booster up the Second Follow up Response Rate","phase":"","overall_status":"COMPLETED","enrollment_count":1246,"lead_sponsor_name":"The University of Hong Kong","has_results":false},{"nct_id":"NCT03875703","title":"Post-Vaccination Biological Collection","phase":"","overall_status":"RECRUITING","enrollment_count":1200,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT02766816","title":"A Clinical Study Comparing Safety and Immunogenicity of bOPV of Bilthoven Biologicals","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1120,"lead_sponsor_name":"Bilthoven Biologicals","has_results":false},{"nct_id":"NCT03522246","title":"A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1097,"lead_sponsor_name":"pharmaand GmbH","has_results":true},{"nct_id":"NCT04881019","title":"PRediction Of Glycemic RESponse Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1070,"lead_sponsor_name":"Scripps Translational Science Institute","has_results":false},{"nct_id":"NCT05470907","title":"Registry for Hemoperfusion of Covid-19 ICU Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1050,"lead_sponsor_name":"Croatian Society for Organ Support","has_results":false},{"nct_id":"NCT04033224","title":"Use of EBPT in Critically Ill Patients With AKI and/or Multiorgan Failure","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Careggi Hospital","has_results":false},{"nct_id":"NCT00853918","title":"Clinical Practice Intensity: Comparing Veterans Affairs (VA) to Private Sector Physicians","phase":"NA","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"VA Office of Research and Development","has_results":false},{"nct_id":"NCT04852796","title":"Efficacy and Safety of the Anti- COVID-19 Vaccin in Clinical Hematology Patients","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Centre Hospitalier de Cornouaille","has_results":false},{"nct_id":"NCT04580680","title":"Extracorporeal Blood Purification Therapy in Critically Ill Patients (GlobalARRT)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Careggi Hospital","has_results":false},{"nct_id":"NCT06993467","title":"Oxygen Delivery During Cardiopulmonary Bypass And Inflammatory Reaction After Cardiac Surgery","phase":"","overall_status":"COMPLETED","enrollment_count":908,"lead_sponsor_name":"Azienda Ospedaliero, Universitaria Ospedali Riuniti","has_results":false},{"nct_id":"NCT02852902","title":"Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to ESBL- or Carbapenemase-producing Enterobacterales in Solid Organ Transplantation: an Observational Multinational Study.","phase":"","overall_status":"COMPLETED","enrollment_count":820,"lead_sponsor_name":"Spanish Network for Research in Infectious Diseases","has_results":false},{"nct_id":"NCT05642117","title":"Pediatric Telephone Center Board 15","phase":"","overall_status":"COMPLETED","enrollment_count":785,"lead_sponsor_name":"University Hospital, Brest","has_results":false},{"nct_id":"NCT03930017","title":"Pregnancy, Arsenic and Immune Response","phase":"","overall_status":"COMPLETED","enrollment_count":784,"lead_sponsor_name":"Johns Hopkins Bloomberg School of Public Health","has_results":false},{"nct_id":"NCT06118034","title":"Effect of Colchicine on Perioperative Anti-inflammatory Organ Injury in Cardiac Surgery","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":768,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT05220319","title":"CORTERAS STUDY: The Effect of Corticosteroids on Early Recovery After Major Surgery in Elderly Patients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":751,"lead_sponsor_name":"Ziekenhuis Oost-Limburg","has_results":false},{"nct_id":"NCT06755567","title":"Application of MRI Radiomics Features in Neoadjuvant Therapy of Head and Neck Squamous Cell Carcinoma","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":750,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05212766","title":"Role of the Oral Microbiome & Mucosal Immunity in COVID-19 Disease","phase":"","overall_status":"UNKNOWN","enrollment_count":750,"lead_sponsor_name":"King's College London","has_results":false},{"nct_id":"NCT07070180","title":"Analysis of Psychoneuroimmunological Parameters of Health in Specific Population Groups in Slovakia","phase":"","overall_status":"COMPLETED","enrollment_count":700,"lead_sponsor_name":"Comenius University","has_results":false},{"nct_id":"NCT02925195","title":"Individualized Response to Vitamin D Treatment Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":666,"lead_sponsor_name":"University of Washington","has_results":true},{"nct_id":"NCT03493880","title":"The Analysis of Immuno-Nutrition Index in Advanced Gastric Cancer Receiving Preoperative Treatments","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Peking University","has_results":false},{"nct_id":"NCT03780712","title":"Immune Dysfunction in Newborn Sepsis","phase":"","overall_status":"COMPLETED","enrollment_count":585,"lead_sponsor_name":"BioMérieux","has_results":false},{"nct_id":"NCT05020210","title":"Effect of Early Treatment With Sivelestat Sodium in ARDS Patients","phase":"","overall_status":"UNKNOWN","enrollment_count":560,"lead_sponsor_name":"Nanfang Hospital, Southern Medical University","has_results":false},{"nct_id":"NCT04182906","title":"Pediatric ACEs Screening and Resiliency Study","phase":"NA","overall_status":"COMPLETED","enrollment_count":555,"lead_sponsor_name":"UCSF Benioff Children's Hospital Oakland","has_results":false},{"nct_id":"NCT05462730","title":"Pulse Glucocorticoid Therapy in Patients With ST-Segment Elevation Myocardial Infarction","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":530,"lead_sponsor_name":"Thomas Engstrom","has_results":true},{"nct_id":"NCT06195267","title":"Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Nanjing Medical University","has_results":false},{"nct_id":"NCT06434701","title":"Severe COVID-19 Infection in Children Presenting to EDs in Israel and England","phase":"NA","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Hadassah Medical Organization","has_results":false},{"nct_id":"NCT06707350","title":"Protective Effect of RIPC Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery (Panda VII)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":500,"lead_sponsor_name":"Nanjing Medical University","has_results":false},{"nct_id":"NCT06248957","title":"SYSTEMS-LEVEL ANALYSES OF IMMUNE DYSREGULATION","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"Karolinska Institutet","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}